Full text is available at the source.
Abstract
A case of acute hepatocellular liver injury occurred in a young female after initiating tirzepatide therapy for weight loss.
- Tirzepatide is a dual receptor agonist approved for type-2 diabetes and weight management.
- Common side effects include gastrointestinal symptoms such as nausea and vomiting.
- Reported cases of liver injury associated with tirzepatide are exceedingly rare.
- The patient experienced recurrent abdominal pain and had a hepatocellular pattern of liver injury.
- Symptoms resolved and liver enzymes normalized within 3 weeks after presentation.
- This case highlights the potential for drug-induced liver injury with newer treatments.
Simplified